心血管医学中的SGLT2抑制剂：万灵药还是潘多拉魔盒？

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

British journal of hospital medicine Pub Date : 2024-11-30 Epub Date: 2024-11-13 DOI:10.12968/hmed.2024.0546

Stella de Aguiar Trigueirinho Ferreira, Lucas Lentini Herling de Oliveira, Arthur Cicupira Rodrigues de Assis, Paulo Rogério Soares, Thiago Luis Scudeler

{"title":"心血管医学中的SGLT2抑制剂：万灵药还是潘多拉魔盒？","authors":"Stella de Aguiar Trigueirinho Ferreira, Lucas Lentini Herling de Oliveira, Arthur Cicupira Rodrigues de Assis, Paulo Rogério Soares, Thiago Luis Scudeler","doi":"10.12968/hmed.2024.0546","DOIUrl":null,"url":null,"abstract":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are antidiabetic agents that effectively lower blood glucose levels in patients with Type 2 Diabetes Mellitus (T2DM). Beyond their glycemic control properties, SGLT2 inhibitors have demonstrated significant cardiovascular benefits, including reductions in major adverse cardiovascular events. However, the limitations of the pivotal trials investigating these outcomes have not been fully explored. This letter aims to critically assess the major randomized clinical trials that evaluated the cardiovascular effects of SGLT2 inhibitors, highlighting both their strengths and limitations.","PeriodicalId":9256,"journal":{"name":"British journal of hospital medicine","volume":"85 11","pages":"1-10"},"PeriodicalIF":1.0000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SGLT2 Inhibitors in Cardiovascular Medicine: Panacea or Pandora's Box?\",\"authors\":\"Stella de Aguiar Trigueirinho Ferreira, Lucas Lentini Herling de Oliveira, Arthur Cicupira Rodrigues de Assis, Paulo Rogério Soares, Thiago Luis Scudeler\",\"doi\":\"10.12968/hmed.2024.0546\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are antidiabetic agents that effectively lower blood glucose levels in patients with Type 2 Diabetes Mellitus (T2DM). Beyond their glycemic control properties, SGLT2 inhibitors have demonstrated significant cardiovascular benefits, including reductions in major adverse cardiovascular events. However, the limitations of the pivotal trials investigating these outcomes have not been fully explored. This letter aims to critically assess the major randomized clinical trials that evaluated the cardiovascular effects of SGLT2 inhibitors, highlighting both their strengths and limitations.\",\"PeriodicalId\":9256,\"journal\":{\"name\":\"British journal of hospital medicine\",\"volume\":\"85 11\",\"pages\":\"1-10\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of hospital medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12968/hmed.2024.0546\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of hospital medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/hmed.2024.0546","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）是一种抗糖尿病药物，可有效降低2型糖尿病（T2DM）患者的血糖水平。除了其血糖控制特性外，SGLT2抑制剂还显示出显著的心血管益处，包括减少主要不良心血管事件。然而，调查这些结果的关键试验的局限性尚未得到充分探讨。本信函旨在批判性地评估评估SGLT2抑制剂心血管作用的主要随机临床试验，强调其优势和局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

SGLT2 Inhibitors in Cardiovascular Medicine: Panacea or Pandora's Box?

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are antidiabetic agents that effectively lower blood glucose levels in patients with Type 2 Diabetes Mellitus (T2DM). Beyond their glycemic control properties, SGLT2 inhibitors have demonstrated significant cardiovascular benefits, including reductions in major adverse cardiovascular events. However, the limitations of the pivotal trials investigating these outcomes have not been fully explored. This letter aims to critically assess the major randomized clinical trials that evaluated the cardiovascular effects of SGLT2 inhibitors, highlighting both their strengths and limitations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

British journal of hospital medicine 医学-医学：内科

CiteScore

1.50

自引率

0.00%

发文量

176

审稿时长

4-8 weeks

期刊介绍： British Journal of Hospital Medicine was established in 1966, and is still true to its origins: a monthly, peer-reviewed, multidisciplinary review journal for hospital doctors and doctors in training. The journal publishes an authoritative mix of clinical reviews, education and training updates, quality improvement projects and case reports, and book reviews from recognized leaders in the profession. The Core Training for Doctors section provides clinical information in an easily accessible format for doctors in training. British Journal of Hospital Medicine is an invaluable resource for hospital doctors at all stages of their career. The journal is indexed on Medline, CINAHL, the Sociedad Iberoamericana de Información Científica and Scopus.